Home
Home
Share Prices
Share Prices
UK Indices
Share Risers
Share Fallers
Stock Tips
Stock Tips
Research
Share Chat
Share Chat
General Chat
Today's Hot Chat Topics
Top Recommended
FX
Crypto
News New
News
RNS
RNS
Media
Media
Investments
Investment Trusts
Private Markets
- JP Jenkins
- Asset Match
Alternative Investments
- Alternative Investments
- Alternative Investment Articles
Trading
Brokers
Members
Free Membership
Premium Membership
Member Benefits

Participate in Share Chat.
Set up virtual watchlists and portfolios
See more trades and share info.

Register for FREE Now

Sign In

Sign In Register for Free

Join our 300,000+ users: Register for FREE

Sign In

Sign In Get Live Data

Less Ads, More Data, More Tools Register for FREE

REMOVE ADS

Home
Share Prices
AQSE Share Prices
Euronext
US Share Prices
Stock Tips
Share Chat
FX
News & RNS
Media
Trading Brokers
Finance Tools
Members

Latest Share Chat

GGP. Sleepy don failed yet again ...
NANO. 'What is hard to avoid, howe...
ITM. Steep falls expected today !...
AVCT. This narrative twisting when...
HPOW. Straight out of ChatGPT. Bor...
ZEN. From today's RNS: "In the Co...
AVCT. FUD MAN at it early doors 🤣🤣...
MATD. If you really want to unders...
PREM. Another well thought out and...
NEO. The AI correction will drag ...

REMOVE ADS

Share Prices
VSN.L Share Price
VSN.L Share News

VSN.L Share News (VSN)

There are 0 new News articles. Click here to refresh the page.

VSN Share
Price
VSN Share
News0
VSN Share
Chat0
VSN Share
Trades0
VSN
Live RNS0
VSN Share
Charts
VSN Broker
Ratings0
VSN Directors
Deals0
VSN Financial
Diary
VSN
Fundamentals
VSN Short
Positions0
VSN
Media0
VSN Company
Research0
VSN Company
Timeline0

VSN.L Information

There is currently no data for VSN

REMOVE ADS

VSN.L News

Verseon gets approval for VE-1902 clinical trial

13 Sep 2018

Verseon gets approval for VE-1902 clinical trial

(Sharecast News) - Technology-based pharmaceutical company Verseon has received ethics committee approval and acknowledgement from the Therapeutic Goo...

Verseon losses widen as VE-1902 trials continue

8 Aug 2018

Verseon losses widen as VE-1902 trials continue

(Sharecast News) - Pharmaceutical company Verseon said interim losses widened 15.9% to $10.2m as the US-based firm's operating expenses increased 7.37...

Verseon granted two important US patents

4 Jan 2017

Verseon granted two important US patents

(ShareCast News) - Technology-based pharmaceutical company Verseon announced on Wednesday that the United States Patent and Trademark Office has grant...

Verseon Corp Gets Positive Results From Study Of Safer Blood Thinner

23 Nov 2016

Verseon Corp Gets Positive Results From Study Of Safer Blood Thinner

Verseon Sees "Significant Progress" With Expansion As Loss Narrows

7 Mar 2016

Verseon Sees "Significant Progress" With Expansion As Loss Narrows

Verseon Presents Positive Preclinical Thrombin Inhibitors Data

29 Feb 2016

Verseon Presents Positive Preclinical Thrombin Inhibitors Data

Verseon To Present New Drug Candidate Data In Paris

10 Feb 2016

Verseon To Present New Drug Candidate Data In Paris

Verseon Reports Narrowed Operating Loss In Maiden Interim Results

7 Sep 2015

Verseon Reports Narrowed Operating Loss In Maiden Interim Results

12

Follow the stocks that matter to you

Create a free LSE account to:

Track shares with a personal watchlist
Join investor discussions
See more trading activity
Receive free RNS Alerts

Already a member? Log in

Create Free Account

Create your free account

Or Continue with Email

Email Address

Password

Sign me up for the FREE market reports I agree to the T&C's and Privacy Policy Marketing I am happy to receive emails from London South East I am happy to receive emails from selected third parties

Already have an account? Sign In

Stay Informed!

With our newsletters and social media channels.

Daily Market Report (Weekday Evenings)Week Ahead (Sunday Evening)

Navigation

Home
Share Prices
Share Chat
FX
News
Blogs
RNS
Media
Members

Share Prices

Financial Diary
Stock Picker
Company Lookup
Broker Ratings
UK Industry Sectors
Stock Tips

Chat

Share Chat

Members

Login
Register
Premium Services

Live Data

From:

£22.90

monthly and annual
subscriptions available.

Get Live Data Now

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk. The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates. London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.

Contact Us
About Us
Advertise With Us
focusIR
Sitemap
Terms & Conditions
Cookies
Privacy
About this website design

MobileTablet View

Please enter at least 2 characters

No results found

Search results

Recently viewed

PIMCO Sterling Short Maturity UCITS ETF Dist

Trending

Powerhouse Ener

Login to your account

Or Continue with Email

Email Address

Password

Remember me

Don't have an account? Register for FREE